Colorectal cancer biotech Cancer Prevention Pharmaceuticals files for a $29 million IPO

Cancer Prevention Pharmaceuticals, which is developing treatments for colorectal cancer risk factors, filed on Wednesday with the SEC to raise up to $29 million in an initial public offering. 

The Tucson, AZ-based company, which was founded in 2009 and booked $4 million in sales for the 12 months ended September 30, 2015, plans to list on the NYSE under the symbol CPP. Cancer Prevention Pharmaceuticals filed confidentially on 9/4/2015. Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.